Targeted ocular delivery Leverage Clearside’s SCS Microinjector platform for targeted, non-surgical delivery to the macula, retina, or choroid to enable partnerships with ophthalmic therapeutics developers seeking improved front or back-of-eye drug localization.

Pipeline collaboration Explore co-development or licensing opportunities around Clearside’s small molecule pipeline candidates that can be administered via the SCS Microinjector, expanding partner portfolios with back-of-eye therapies.

In-office procedural model Position SCS injections as an in-office, repeatable alternative to surgical approaches, appealing to clinics aiming to increase patient throughput and reduce procedure-related costs.

EURETINA and ARVO exposure Capitalize on ongoing scientific presentations and abstracts at major ophthalmology conferences to identify early-adopter clinics and key opinion leaders for pilot studies and adoption of the SCS platform.

Financial and leadership signals Note steady funding and governance changes, including board leadership updates, as indicators of potential stability and strategic focus that may align with partner-led financing or co-marketing arrangements.